Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options

References

• PayerJKillingerZBone changes in hypercorticismRheumatol199913181183
   Google Scholar
• Van StaaTPLeufkensHGCooperCThe epidemiology of corticosteroid-induced osteoporosis: a meta-analysisOsteoporos Int20021377778712378366
   PubMed Web of Science ®Google Scholar
• Dale CarbonareLArlotMEChavassieuxPMComparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosisJ Bone Miner Res2001169710311149495
   PubMed Web of Science ®Google Scholar
• Van StaaTPLeufkensHGMAbenhaimLOral corticosteroids and fracture risk: relationship to daily and cumulative dosesRheumatol20003913831389
   PubMed Web of Science ®Google Scholar
• Van StaaTLeufkensHGMAbenhaimLUse of oral corticosteroids and risk of fracturesJ Bone Miner Res200015993100010841167
   PubMed Web of Science ®Google Scholar
• De GregórioLHLacativaPGMelazziACGlucocorticoid-induced osteoporosisArq Bras Endocrinol Metabol20065079380117117304
   PubMedGoogle Scholar
• Van StaaTPThe pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosisCalcif Tissue Int20067912913716969593
   PubMed Web of Science ®Google Scholar
• EastellRReidDMCompstonJECooperCA UK consensus gruop on management of glucocorticoid-induced osteoporosis: an updateJ Intern Med19982442712929797491
   PubMed Web of Science ®Google Scholar
• HooymanJRMeltonLJNelsonAMO’FallonWMRiggsBLFractures after rheumatoid arthritis – a population based studyArthritis Rheum198427135313616508860
   PubMed Web of Science ®Google Scholar
• CooperCCouplandCMitchellMRheumatoid arthritis, corticosteroid therapy and the risk of hip fractureAnn Rheum Dis19955449527880122
   PubMed Web of Science ®Google Scholar
• PayerJRovenskýJKillingerZLexicon of Osteoporosis SAP200730
   Google Scholar
• KanisJAJohnellOOdenAFRAX and the assessment of fracture probability in men and women from the UKOsteoporos Int20081938539718292978
   PubMed Web of Science ®Google Scholar
• WeinsteinRSJilkaRLParfittAMManolagasSCInhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids – potential mechanisms of their deleterious effects on boneJ Clin Invest19981022742829664068
   PubMed Web of Science ®Google Scholar
• WeinsteinRSNicholasRWManolagasSCApoptosis of ostecytes on glucocorticoid-induced osteonecrosis of the hipJ Clin Endocrinol Metab2000852907291210946902
   PubMed Web of Science ®Google Scholar
• WeinsteinRSChenJRPowersCCStewartSAPromotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoidsJ Clin Invest20021091041104811956241
   PubMed Web of Science ®Google Scholar
• PlotkinLIWeinsteinRSParfittAMRobersonPKPrevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitoninJ Clin Invest19991041363137410562298
   PubMed Web of Science ®Google Scholar
• MorrisHANeedAGO’LoughlinPDHorowitzMBridgesANordinBECMalabsorption of calcium in corticosteroid-induced osteoporosisCalcif Tissue Int1990463053082110853
   PubMed Web of Science ®Google Scholar
• SambrookPBirminghamJKellyPKemplerSPrevention of corticosteroid osteoporosis – a comparison of calcium, calcitriol and calcitoninN Engl J Med1993328174717527684512
   PubMed Web of Science ®Google Scholar
• PearceGTabenskyDADelmasPDBakerHWSeemanECorticosteroid-induced bone loss in menJ Clin Endocrinol Metab1998838018069506731
   PubMed Web of Science ®Google Scholar
• AlesciSDe MartinoMUIliasIGlucocorticoid-Induced Osteoporosis: From Basic Mechanisms to Clinical AspectsNeuroimmunomodulation20051211915756049
   PubMed Web of Science ®Google Scholar
• HeffernanMPSaagKGRobinsonJKPrevention of osteoporosis associated with chronic glucocorticoid therapyJAMA2006295130016541489
   PubMed Web of Science ®Google Scholar
• Guidelines Writing Group for the Royal College for Physicians of LondonOsteoporosis: Clinical Guidelines for Prevention and TeatmentLondonRoyal College for Physicians2002
   Google Scholar
• AagaardEMLinPModinGWPrevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospitalAm J Med199910745646010569300
   PubMed Web of Science ®Google Scholar
• LeeYHLimYWLingPSInadequate dietary calcium intake in elderly patients with hip fracturesSingapore Med J2007481117112118043839
   PubMedGoogle Scholar
• LemsWFVan VeenGJGerritsMIEffect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteersBr J Rheumatol19983727339487247
   PubMedGoogle Scholar
• RovenskyJPayerJBisphosphonates. Dictionary of RheumatologyNewYorkSpringerWien200924
   Google Scholar
• MokCCTongKHToCHRisedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trialOst Int200819357364
   PubMed Web of Science ®Google Scholar
• RingeJDDorstAFaberHIntermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative studyOst Int200314801807
   PubMed Web of Science ®Google Scholar
• ReidDMHughesRALaanRFEfficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trialJ Bone Miner Res2000151006101310841169
   PubMed Web of Science ®Google Scholar
• ReidDMAdamiSDevogelaerJPChinesAARisedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapyCalcif Tissue Int20016924224711730260
   PubMed Web of Science ®Google Scholar
• BodyJJGaichGAScheeleWHA randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone 1–34) with alendronate in postmenopausal women with osteoporosisJ Clin Endocrinol Metab2002874528453512364430
   PubMed Web of Science ®Google Scholar
• PayerJČiernyDKillingerZŠulkováIBehuliakMCelecPPreferences of patients with postmenopausal osteoporosis treated with bisphosphonates – the VIVA II studyJIMR2009371225122919761708
   PubMed Web of Science ®Google Scholar
• PayerJKillingerZŠulkováICelecPPreferences of patients receiving bisphosphonates – How to influence the therapeutic adherenceBiomed Pharmacother20086212212417888616
   PubMed Web of Science ®Google Scholar
• RovenskyJPayerJOsteonecrosis of the Jaw. Dictionary of RheumatologyNewYorkSpringerWien2009158
   Google Scholar
• MillerPDBisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis: Bisphosphonate Safety OsteoporosisElsevier200817331736
   Google Scholar
• AbrahamsenBEikenPEastellRSubtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a registered-based national cohort studyJ Bone Miner Res2009241095110219113931
   PubMed Web of Science ®Google Scholar
• SinghAPOral bisphosphonates may cause esophageal cancerN Engl J Med200913608990
   Google Scholar
• AdachiJDBensenWGBellMJSalmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosisBr J Rheumatol1997362552599133941
   PubMedGoogle Scholar
• CruseLMValerianoJVaseyFBPrevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in menJ Clin Rheumatol20061222122517023807
   PubMed Web of Science ®Google Scholar
• YamadaHLong-term effect of 1 alpha-hydroxyvitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosisNippon Naibunpi Gakkai Zasshi1989656036142792461
   PubMedGoogle Scholar
• GrotzWHRumpLCNiessenASchmidt-GaykHTreatment of osteopenia and osteoporosis after kidney transplantationTransplantation199866100410089808483
   PubMed Web of Science ®Google Scholar
• Garcia-DelgadoIPrietoSGil-FraguasLRoblesECalcitonin, etidronate and calcidiol treatment in bone loss after cardiac transplantationCalcif Tissue Int1997601551599056163
   PubMed Web of Science ®Google Scholar
• BiandaTLinkaAJungaGBrunnerHPrevention in osteoporosis in heart transplantation recipients: a comparison of calcitriol with calcitonin and pamidronateCalcif Tissue Int20006711612110920215
   PubMed Web of Science ®Google Scholar
• VälimäkiMJKinnunenKTähteläRLoyttyniemiEA prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitoninOsteoporos Int19991012813610501793
   PubMed Web of Science ®Google Scholar
• CremerJStruberMWagenbrethIMnischelskyJProgression of steroid-associated osteoporosis after heart transplantationAnn Thoracic Surg199967130133
   Web of Science ®Google Scholar
• ValeroMALoinazCLarrodenaLLeonMCalcitonin and bisphosphonate treatment in bone loss after liver transplantationCalcif Tissue Int19955715197671159
   PubMed Web of Science ®Google Scholar
• RizzatoGTosiGSchiraldiGMontemurroLSistiDSBone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosisSarcoidosis19885991033227195
   PubMedGoogle Scholar
• LuengoMPonsFMartinez de OsabaMJPicadoCPrevention of further bone mass loss by nasal calcitonin in patients on longterm glucocorticoid therapy for asthma: a two year follow up studyThorax199449109911027831624
   PubMed Web of Science ®Google Scholar
• CharlwoodCManningEMCRobinsonJFraserWDComparison of pamidronate, calcitonin and cyclical etidronate in the treatment of osteoporosis associated with steroid therapyJ Bone Miner Res199712Suppl 1S510
   Google Scholar
• HealeyJHPagetSAWilliams-RussoPSzatrowskiTPA randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumaticaCalcif Tissue Int19965873808998681
   PubMed Web of Science ®Google Scholar
• KotaniemiAPiiraainenHPaimelaLLeirisalo-RepoMIs continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy?J Rheumatol199623187518798923359
   PubMed Web of Science ®Google Scholar
• HallGMDanielsMDoyleDVSpectorTDEffect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroidsArthritis Rheum199437149915057945476
   PubMed Web of Science ®Google Scholar
• LaneNERoeBGenantHKArnaudCParathyroid hormone treatment reverses glucocorticoid-induced osteoporosis: results of a randomized controlled trialJ Clin Invest1998102162716339788977
   PubMed Web of Science ®Google Scholar
• DrinkwaterBLNilsonKOttSChesnutCHBone mineral density after resumption of menses in amenorrheic womenJAMA19862563803823723725
   PubMed Web of Science ®Google Scholar
• DrinkwaterBLNilsonKChesnutCHBrennerWJShainholtzSSouthworthWBBone mineral content of amenorrheic and eumenorrheic athletesN Engl J Med19843112772816738640
   PubMed Web of Science ®Google Scholar
• DelmasPDBjarnasonNHMitlakBHRavouxACHusterWJDraperMEffects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal womenN Engl J Med1997337164116779385122
   PubMed Web of Science ®Google Scholar
• EttingerBBlackDMMitlakBHKnickerbockerRKNickelsenTGenantHKfor the Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsReduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trialJAMA199928263764510517716
   PubMed Web of Science ®Google Scholar
• ReidIRWattieDJEvansMCStapletonJPTestosterone therapy in glucocorticoid-treated menArch Intern Med1996156117311778639011
   PubMed Web of Science ®Google Scholar
• PetakSMBaskinHJBergmanDADickeyRANankinHA AACE clinical practice guidelines for the evaluation and treatment of hypogonadism in adult male patients. http://www.aace.com/clin/guides/hypogonadism.html. Accessed December 20, 2000.
   Google Scholar
• JinLBriggsSLChandrasekharSChirgadzeNYClawsonDCrystal structure of human parathyroid hormone 1–34 at 0,9-A resolutionJ Biol Chem2000275272382724410837469
   PubMed Web of Science ®Google Scholar
• ČiernyDKillingerZPayerJPlace of teriparatide and intact parathormone in treatment of osteoporosisSlov Lek200717226230
   Google Scholar
• ŠtěpánJGlucocorticoid-induced osteoporosis: New options of prevention and treatmentInterní Med200810323326
   Google Scholar
• PayerJKillingerZBrázdilováKTreatment algorithm of glucocorticoid induced osteoporosisVnitř Lék200955506511
   Google Scholar
• NeerRMClaudeDAJoseRZEffect of Parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med200134414311441
   Web of Science ®Google Scholar
• SaagKGZanchettaJRDevogelaerJPAdlerRASeeKDalskyGPTeriparatide versus Alendronate for Treatment of Glucocorticoid-Induced Osteoporosis: 36-month ResultsN Engl J Med2008Suppl 1S49
   Google Scholar
• OrwollESScheeleWHPaulSThe effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosisJ Bone Miner Res20031891712510800
   PubMed Web of Science ®Google Scholar
• McClungMRSan MartinJMillerPDOpposite bone remodeling effects of teriparatide and alendronate in increasing bone massArch Intern Med20051651762176816087825
   PubMed Web of Science ®Google Scholar
• KeavenyTMDonleyDWHoffmannPFMitlakBHGlassEVSan MartinJAEffects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosisJ Bone Miner Res20072214915717042738
   PubMed Web of Science ®Google Scholar
• O’BrienCAJiaDPlotkinLIGlucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strenghtEndocrinology20041451835184114691012
   PubMed Web of Science ®Google Scholar
• AdachiJDSaagKGDelmasPDTwo-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized double-blind, placebo-controlled extension trialArthritis Rheum20014420221111212161
   PubMed Web of Science ®Google Scholar
• SambrookPNKotowiczMNashPPrevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calciumJ Bone Miner Res20031891992412733733
   PubMed Web of Science ®Google Scholar
• WallachSCohenSReidDMEffects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapyCalcif Tissue Int20006727728511000340
   PubMed Web of Science ®Google Scholar
• NeerRMArnaudCDZanchettaJREffect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med20013441434144111346808
   PubMed Web of Science ®Google Scholar
• SaagKGEmkeyRSchnitzerTJAlendronate for the prevention and treatment of glucocorticoid-induced osteoporosisN Engl J Med19983392922999682041
   PubMed Web of Science ®Google Scholar
• CohenSLevyRMKellerMRisedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, paralel-group studyArthritis Rheum1999422309231810555025
   PubMed Web of Science ®Google Scholar
• de NijsRNJacobsJWLemsWFAlendronate or alfacalcidol in glucocorticoid-induced osteoporosisN Engl J Med200635567568416914703
   PubMed Web of Science ®Google Scholar
• SaagKGShaneEBoonenSTeriparatide or alendronate in glucocorticoid-induced osteoporosisN Engl J Med20073572028203918003959
   PubMed Web of Science ®Google Scholar
• VahleJLSatoMLongGGSkeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for two years and relevance to human safetyToxicol Pathol20023031232112051548
   PubMed Web of Science ®Google Scholar
• BetancourtMWirfelKLRaymondAKOsteosarcoma of bone in a patient with primary hyperparathyroidism: a case reportJ Bone Miner Res20031816316612510819
   PubMed Web of Science ®Google Scholar
• AdlerRACurtisJWeinsteinRSSaagKGManagement of Glucocorticoid-Induced Osteoporosis in Children OsteoporosisElsevier20081156
   Google Scholar
• KennelKASwigloBAMontoriVMEvidence-based osteoporosi careMarcusRFeldmanDNelsonDARosenCJOsteoporosisThird Ed2Elsevier Academic Press200816291650
   Google Scholar
• Recommendations for the Prevention and Treatment of Glucocorticoid-Induced OsteoporosisAmerican College Of Rheumatology Ad Hoc Committee On Glucocorticoid-Induced OsteoporosisArthritis Rheum2001441496150311465699
   PubMed Web of Science ®Google Scholar
• SaagKGPrevention of glucocorticoid-induced osteoporosisSouth Med J20049755555815255421
   PubMedGoogle Scholar
• GeusensPPde NijsRNJLemsWFPrevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for RheumatologyAnn Rheum Dis20046332432514962971
   PubMed Web of Science ®Google Scholar
• CanalisEMazziottiGGuitinaAGlucocorticoid-induced osteoporosis: pathophysiology and therapyOsteoporosis Int20071813191328
   PubMed Web of Science ®Google Scholar